HUE043809T2 - Eljárás lipid-nukleinsav részecskék steril elõállítására - Google Patents

Eljárás lipid-nukleinsav részecskék steril elõállítására

Info

Publication number
HUE043809T2
HUE043809T2 HUE12829180A HUE12829180A HUE043809T2 HU E043809 T2 HUE043809 T2 HU E043809T2 HU E12829180 A HUE12829180 A HU E12829180A HU E12829180 A HUE12829180 A HU E12829180A HU E043809 T2 HUE043809 T2 HU E043809T2
Authority
HU
Hungary
Prior art keywords
sterilely
nucleic acid
acid particles
producing lipid
lipid
Prior art date
Application number
HUE12829180A
Other languages
English (en)
Inventor
Victor Knopov
Richard Witte
Priya Karmali
Robin Lee
David Webb
Original Assignee
Nitto Denko Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitto Denko Corp filed Critical Nitto Denko Corp
Publication of HUE043809T2 publication Critical patent/HUE043809T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • B01J13/04—Making microcapsules or microballoons by physical processes, e.g. drying, spraying
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • B01J13/06—Making microcapsules or microballoons by phase separation
    • B01J13/12—Making microcapsules or microballoons by phase separation removing solvent from the wall-forming material solution
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Dispersion Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
HUE12829180A 2011-11-04 2012-11-02 Eljárás lipid-nukleinsav részecskék steril elõállítására HUE043809T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161556124P 2011-11-04 2011-11-04

Publications (1)

Publication Number Publication Date
HUE043809T2 true HUE043809T2 (hu) 2019-09-30

Family

ID=47178988

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE12829180A HUE043809T2 (hu) 2011-11-04 2012-11-02 Eljárás lipid-nukleinsav részecskék steril elõállítására

Country Status (21)

Country Link
US (1) US8956572B2 (hu)
EP (4) EP2773328A2 (hu)
JP (3) JP6133883B2 (hu)
KR (2) KR102046968B1 (hu)
CN (2) CN103906504B (hu)
AU (2) AU2012356239B2 (hu)
CA (2) CA2853685C (hu)
CY (1) CY1121495T1 (hu)
DK (1) DK2773326T3 (hu)
ES (1) ES2721325T3 (hu)
HR (1) HRP20190481T1 (hu)
HU (1) HUE043809T2 (hu)
LT (1) LT2773326T (hu)
PL (1) PL2773326T3 (hu)
PT (1) PT2773326T (hu)
RS (1) RS58562B1 (hu)
RU (2) RU2647476C2 (hu)
SI (1) SI2773326T1 (hu)
TR (1) TR201904389T4 (hu)
TW (3) TWI618548B (hu)
WO (2) WO2013064911A2 (hu)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA3162352A1 (en) 2010-10-01 2012-04-05 Modernatx, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9428535B2 (en) 2011-10-03 2016-08-30 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9579338B2 (en) 2011-11-04 2017-02-28 Nitto Denko Corporation Method of producing lipid nanoparticles for drug delivery
EP2791160B1 (en) 2011-12-16 2022-03-02 ModernaTX, Inc. Modified mrna compositions
US9320297B2 (en) 2012-03-22 2016-04-26 Lemniscate Innovations Llc Spherification/reverse spherification automated and integrated system and method
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
AU2013243946A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of membrane proteins
LT3489220T (lt) 2012-06-08 2021-09-27 Nitto Denko Corporation Lipidai, skirti terapinėms agento pristatymo vaisto formoms
LT2922554T (lt) 2012-11-26 2022-06-27 Modernatx, Inc. Terminaliai modifikuota rnr
KR20150132131A (ko) 2013-02-05 2015-11-25 1글로브 헬스 인스티튜트 엘엘씨 약물 전달 담체로서 생체분해가능하고 임상적으로 상용가능한 나노입자
EP2971010B1 (en) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
WO2014152031A1 (en) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Ribonucleic acid purification
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
PL3019619T3 (pl) 2013-07-11 2022-01-10 Modernatx, Inc. Kompozycje zawierające syntetyczne polinkleotydy kodujące białka powiązane z crispr i syntetyczne sgrna oraz sposoby ich stosowania
US20160194625A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Chimeric polynucleotides
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
US10195291B2 (en) 2013-09-24 2019-02-05 Alnylam Pharmaceuticals, Inc. Compositions and methods for the manufacture of lipid nanoparticles
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
CA2926218A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
CN103599549A (zh) * 2013-11-22 2014-02-26 大连民族学院 一种siRNA/抗癌药物联合转运复合载体及其制备方法和应用
EP3981437A1 (en) 2014-04-23 2022-04-13 ModernaTX, Inc. Nucleic acid vaccines
EP3164112A1 (en) * 2014-07-02 2017-05-10 Shire Human Genetic Therapies, Inc. Encapsulation of messenger rna
US10342761B2 (en) * 2014-07-16 2019-07-09 Novartis Ag Method of encapsulating a nucleic acid in a lipid nanoparticle host
CA2955250A1 (en) 2014-07-16 2016-01-21 Moderna Therapeutics, Inc. Chimeric polynucleotides
WO2016014846A1 (en) 2014-07-23 2016-01-28 Moderna Therapeutics, Inc. Modified polynucleotides for the production of intrabodies
WO2016045732A1 (en) * 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
SG11201705312PA (en) * 2014-12-29 2017-07-28 Bonac Corp Composition containing nucleic acid molecule stably
EP3262424A4 (en) * 2015-02-24 2019-03-13 The University of British Columbia MICROFLUIDIC SYSTEM WITH CONTINUOUS FLOW
JP2018525209A (ja) 2015-04-28 2018-09-06 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア 使い捨てマイクロ流体カートリッジ
LT3324932T (lt) * 2015-07-22 2021-04-26 Nitto Denko Corporation Kompozicijos ir būdai, skirti liofilinėms nanodalelių formoms
WO2017031232A1 (en) 2015-08-17 2017-02-23 Modernatx, Inc. Methods for preparing particles and related compositions
US9938572B1 (en) * 2015-09-08 2018-04-10 Raindance Technologies, Inc. System and method for forming an emulsion
EP3736261B1 (en) 2015-09-17 2023-10-11 ModernaTX, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
AU2016342045A1 (en) 2015-10-22 2018-06-07 Modernatx, Inc. Human cytomegalovirus vaccine
WO2017099823A1 (en) 2015-12-10 2017-06-15 Modernatx, Inc. Compositions and methods for delivery of therapeutic agents
HUE057877T2 (hu) 2015-12-22 2022-06-28 Modernatx Inc Vegyületek és készítmények terápiás szerek intracelluláris bejuttatására
LT3394093T (lt) 2015-12-23 2022-04-25 Modernatx, Inc. Ox40 ligandus koduojančių polinukleotidų naudojimo būdai
CA3009691C (en) 2016-01-06 2021-12-07 The University Of British Columbia Bifurcating mixers and methods of their use and manufacture
MA43587A (fr) 2016-01-10 2018-11-14 Modernatx Inc Arnm thérapeutiques codant pour des anticorps anti-ctla-4
US10689873B2 (en) 2016-03-10 2020-06-23 Lonza Ltd Customizable facility
EA201892029A1 (ru) 2016-03-10 2019-03-29 Лонца Лтд. Перенастраиваемое оборудование
WO2017223135A1 (en) * 2016-06-24 2017-12-28 Modernatx, Inc. Lipid nanoparticles
US11191849B2 (en) 2016-06-30 2021-12-07 Arbutus Biopharma Corporation Compositions and methods for delivering messenger RNA
IL307217A (en) 2016-08-02 2023-11-01 Lonza Ag Customizable facility
CN110312799A (zh) 2016-08-17 2019-10-08 博德研究所 新型crispr酶和系统
US11352647B2 (en) 2016-08-17 2022-06-07 The Broad Institute, Inc. Crispr enzymes and systems
EP3500312B1 (en) * 2016-08-18 2024-04-10 Troy Bremer Delivery of urea to cells of the macula and retina using liposome constructs
EP3315125A1 (en) * 2016-10-31 2018-05-02 Silence Therapeutics (London) Ltd Lipid nanoparticle formulation
WO2018089540A1 (en) * 2016-11-08 2018-05-17 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
ES2940259T3 (es) 2017-03-15 2023-05-04 Modernatx Inc Compuesto y composiciones para la administración intracelular de agentes terapéuticos
US11969506B2 (en) 2017-03-15 2024-04-30 Modernatx, Inc. Lipid nanoparticle formulation
ES2911186T3 (es) 2017-03-15 2022-05-18 Modernatx Inc Formas cristalinas de aminolípidos
WO2018191750A2 (en) 2017-04-14 2018-10-18 The Broad Institute Inc. Novel delivery of large payloads
US11786607B2 (en) 2017-06-15 2023-10-17 Modernatx, Inc. RNA formulations
AU2017423053A1 (en) * 2017-07-10 2020-01-23 Immunovaccine Technologies Inc. Pharmaceutical compositions, methods for preparation using lipid vesicle particles of defined size, and uses thereof
CA3071968A1 (en) 2017-08-04 2019-02-07 Kyowa Kirin Co., Ltd. Nucleic acid-containing lipid nanoparticle
JP2019043216A (ja) 2017-08-30 2019-03-22 いすゞ自動車株式会社 ステアリング装置
WO2019046809A1 (en) 2017-08-31 2019-03-07 Modernatx, Inc. METHODS OF MANUFACTURING LIPID NANOPARTICLES
TW201927288A (zh) 2017-10-20 2019-07-16 德商拜恩迪克Ｒｎａ製藥有限公司 適用於治療之微脂體ｒｎａ配製物的製備及儲存
CN111565833B (zh) 2017-11-01 2023-04-07 国立大学法人大阪大学 用于制造具有期望的粒径的脂质颗粒的方法及装置的开发
AU2017438994A1 (en) * 2017-11-09 2020-05-28 Immunovaccine Technologies Inc. Pharmaceutical compositions, methods for preparation comprising sizing of lipid vesicle particles, and uses thereof
US20210363260A1 (en) 2017-11-13 2021-11-25 The Broad Institute, Inc. Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
US10968257B2 (en) 2018-04-03 2021-04-06 The Broad Institute, Inc. Target recognition motifs and uses thereof
WO2019204451A1 (en) * 2018-04-17 2019-10-24 Carnegie Mellon University Enhanced lipid nanoparticle drug delivery using a negatively charged polymer
AU2019333042A1 (en) * 2018-08-29 2021-03-04 Translate Bio, Inc. Improved process of preparing mRNA-loaded lipid nanoparticles
CA3113353A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. High-purity peg lipids and uses thereof
CA3113025A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. Peg lipids and uses thereof
JP2022501367A (ja) * 2018-09-20 2022-01-06 モデルナティエックス インコーポレイテッドModernaTX, Inc. 脂質ナノ粒子の調製及びその投与方法
WO2020061426A2 (en) * 2018-09-21 2020-03-26 Acuitas Therapeutics, Inc. Systems and methods for manufacturing lipid nanoparticles and liposomes
PL3864163T3 (pl) 2018-10-09 2024-05-20 The University Of British Columbia Kompozycje i układy zawierające pęcherzyki zdolne do transfekcji wolne od rozpuszczalników organicznych i detergentów oraz związane z nimi sposoby postępowania
KR20210090634A (ko) * 2018-10-19 2021-07-20 트랜슬레이트 바이오 인코포레이티드 전령 rna의 무펌프 캡슐화
JP2022519557A (ja) * 2019-01-31 2022-03-24 モデルナティエックス インコーポレイテッド 脂質ナノ粒子の調製方法
WO2020191102A1 (en) 2019-03-18 2020-09-24 The Broad Institute, Inc. Type vii crispr proteins and systems
WO2020191103A1 (en) * 2019-03-19 2020-09-24 Arcturus Therapeutics, Inc. Method of making lipid-encapsulated rna nanoparticles
EP3965738A1 (en) 2019-05-07 2022-03-16 Universidade do Minho Method for production of liposomes
WO2020236972A2 (en) 2019-05-20 2020-11-26 The Broad Institute, Inc. Non-class i multi-component nucleic acid targeting systems
ES2918001A2 (es) 2019-08-14 2022-07-13 Acuitas Therapeutics Inc Nanoparticulas lipidicas mejoradas para el suministro de acidos nucleicos
CN114929205A (zh) 2019-09-06 2022-08-19 世代生物公司 包括末端封闭式dna和可切割脂质的脂质纳米颗粒组合物及其使用方法
JP7271374B2 (ja) * 2019-09-10 2023-05-11 株式会社東芝 分析方法、分析基体、分析キット及び分析装置。
JP2022548304A (ja) 2019-09-19 2022-11-17 モデルナティエックス インコーポレイテッド 治療薬の細胞内送達のための分岐状尾部脂質化合物及び組成物
CN114787127B (zh) 2019-11-22 2024-04-26 世代生物公司 可电离脂质及其纳米颗粒组合物
KR102409145B1 (ko) * 2020-03-23 2022-06-15 프레스티지바이오로직스 주식회사 항체 의약품 제조 공정을 위한 버퍼 조제 및 이송 시스템
CN111467321A (zh) * 2020-03-26 2020-07-31 深圳市新合生物医疗科技有限公司 一种mRNA核酸类药物胞内递送系统、制备方法和应用
CA3194951A1 (en) 2020-09-13 2022-03-17 Arcturus Therapeutics, Inc. Lipid nanoparticles encapsulation of large rna
CN112843019A (zh) * 2021-01-27 2021-05-28 江苏普瑞康生物医药科技有限公司 一种核酸脂质纳米粒组合物，包含其的药物制剂，及其制备方法和应用
EP4294450A1 (en) * 2021-02-16 2023-12-27 The Johns Hopkins University Methods for preparation of plasmid dna/lipid particles with defined size for in vitro and in vivo transfection
WO2022175366A1 (en) 2021-02-17 2022-08-25 Secoya Technologies Method for producing lipid nanoparticles and lipid nanoparticles resulting therefrom
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
WO2022225368A1 (ko) * 2021-04-22 2022-10-27 (주)인벤티지랩 지질 나노입자의 제조 방법 및 이의 제조 장치
WO2022266032A1 (en) 2021-06-14 2022-12-22 Generation Bio Co. Cationic lipids and compositions thereof
WO2023057596A1 (en) * 2021-10-06 2023-04-13 Leon-Nanodrugs Gmbh Method for preparing lipid nanoparticles
WO2023081526A1 (en) 2021-11-08 2023-05-11 Orna Therapeutics, Inc. Lipid nanoparticle compositions for delivering circular polynucleotides
CN116549626A (zh) * 2022-01-27 2023-08-08 深圳瑞吉生物科技有限公司 一种载核酸脂质纳米颗粒冻干制剂及其制备方法与应用
WO2023161350A1 (en) 2022-02-24 2023-08-31 Io Biotech Aps Nucleotide delivery of cancer therapy
WO2023196818A1 (en) 2022-04-04 2023-10-12 The Regents Of The University Of California Genetic complementation compositions and methods
KR102475540B1 (ko) * 2022-04-26 2022-12-08 주식회사 무진메디 약물이 담지된 지질 나노입자 제조 방법 및 제조 장치
WO2023239756A1 (en) 2022-06-07 2023-12-14 Generation Bio Co. Lipid nanoparticle compositions and uses thereof
WO2024102762A1 (en) 2022-11-08 2024-05-16 Orna Therapeutics, Inc. Lipids and lipid nanoparticle compositions for delivering polynucleotides
WO2024102730A1 (en) 2022-11-08 2024-05-16 Orna Therapeutics, Inc. Lipids and nanoparticle compositions for delivering polynucleotides
WO2024102677A1 (en) 2022-11-08 2024-05-16 Orna Therapeutics, Inc. Circular rna compositions

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01501228A (ja) * 1986-09-18 1989-04-27 リポソーム　テクノロジー，インコーポレイテッド 高濃度リポソーム処理方法
US4781871A (en) * 1986-09-18 1988-11-01 Liposome Technology, Inc. High-concentration liposome processing method
US4895452A (en) 1988-03-03 1990-01-23 Micro-Pak, Inc. Method and apparatus for producing lipid vesicles
EP0706374B1 (en) * 1993-06-30 1997-12-10 Genentech, Inc. Method for preparing liposomes
DE69634084T2 (de) 1995-06-07 2005-12-08 Inex Pharmaceuticals Corp. Herstellung von lipid-nukleinsäure partikeln duch ein hydrophobische lipid-nukleinsäuree komplexe zwischenprodukt und zur verwendung in der gentransfer
US5981501A (en) 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
US6395302B1 (en) 1996-11-19 2002-05-28 Octoplus B.V. Method for the preparation of microspheres which contain colloidal systems
JP4656675B2 (ja) * 1997-05-14 2011-03-23 ユニバーシティー オブ ブリティッシュ コロンビア 脂質小胞への荷電した治療剤の高率封入
US6855296B1 (en) 1998-11-13 2005-02-15 Optime Therapeutics, Inc. Method and apparatus for liposome production
JP2002529240A (ja) 1998-11-13 2002-09-10 オプタイム セラピュウティクス， インコーポレイテッド リポソーム生成のための方法および装置
IL147089A0 (en) * 1999-07-15 2002-08-14 Inex Pharmaceuticals Corp Methods of preparing lipid-encapsulated therapeutic agents
US7094423B1 (en) 1999-07-15 2006-08-22 Inex Pharmaceuticals Corp. Methods for preparation of lipid-encapsulated therapeutic agents
EP1203614A1 (de) 2000-11-03 2002-05-08 Polymun Scientific Immunbiologische Forschung GmbH Verfahren und Vorrichtung zur Herstellung von Lipidvesikeln
EP1306127B2 (en) 2001-10-26 2011-09-07 OctoPlus PolyActive Sciences B.V. Method for the preparation of purified microparticles
US7223887B2 (en) 2001-12-18 2007-05-29 The University Of British Columbia Multivalent cationic lipids and methods of using same in the production of lipid particles
US20090191259A1 (en) 2002-01-09 2009-07-30 Transave, Inc. Efficient liposomal encapsulation
US6712963B2 (en) 2002-06-14 2004-03-30 Scilog, Llc Single-use manifold for automated, aseptic transfer of solutions in bioprocessing applications
DE60334618D1 (de) 2002-06-28 2010-12-02 Protiva Biotherapeutics Inc Verfahren und vorrichtung zur herstellung von liposomen
FR2856940B1 (fr) * 2003-07-04 2007-02-09 Stedim Sa Systeme clos a usage unique de melange, de stockage et d'homogeneisation de liquides en conditions propres ou steriles
WO2005090403A2 (en) * 2004-03-12 2005-09-29 Biovest International, Inc. Method and apparatus for antibody purification
CN101001945B (zh) 2004-06-04 2012-02-08 艾克塞勒雷克斯公司 一次性生物反应器系统及方法
US7410587B2 (en) 2004-08-03 2008-08-12 Scilog, Inc. Liquid handling for filtration and preparative chromatography
US7404969B2 (en) * 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
CA2616877C (en) 2005-07-27 2014-01-28 Protiva Biotherapeutics, Inc. Systems and methods for manufacturing liposomes
AU2006308765B2 (en) * 2005-11-02 2013-09-05 Arbutus Biopharma Corporation Modified siRNA molecules and uses thereof
JP4058108B2 (ja) 2006-04-11 2008-03-05 株式会社バイオメディア リポソーム分散液の製造方法ならびに製造装置
EP1920765A1 (en) 2006-11-07 2008-05-14 Medigene AG Liposome preparation by single-pass process
WO2009086558A1 (en) 2008-01-02 2009-07-09 Tekmira Pharmaceuticals Corporation Improved compositions and methods for the delivery of nucleic acids
JP5322476B2 (ja) 2008-03-31 2013-10-23 テルモ株式会社 リポソームの製造装置およびリポソームの製造方法
US8231787B2 (en) 2008-05-06 2012-07-31 Spf Innovations, Llc Tangential flow filtration system
EP2326331A4 (en) * 2008-08-18 2013-05-15 Merck Sharp & Dohme NOVEL LIPID NANOPARTICLES AND NEW COMPONENTS FOR NUCLEIC ACID ADMINISTRATION
WO2010045512A2 (en) 2008-10-16 2010-04-22 Mdrna , Inc. Processes and compositions for liposomal and efficient delivery of gene silencing therapeutics
TW201021853A (en) * 2008-11-17 2010-06-16 Enzon Pharmaceuticals Inc Releasable cationic lipids for nucleic acids delivery systems
WO2010080724A1 (en) * 2009-01-12 2010-07-15 Merck Sharp & Dohme Corp. Novel lipid nanoparticles and novel components for delivery of nucleic acids
EP2389170B1 (en) * 2009-01-20 2013-11-06 Med Coat AB Coating compostion and use thereof
FR2943560B1 (fr) * 2009-03-24 2011-05-27 Jean Pascal Zambaux Bioreacteur jetable et systeme d'agitation a usage unique
JP5823405B2 (ja) * 2009-11-04 2015-11-25 ザ ユニバーシティ オブ ブリティッシュ コロンビア 核酸含有脂質粒子および関連方法
PT3338765T (pt) * 2009-12-01 2019-03-18 Translate Bio Inc Derivado de esteróide adequado para a administração de arnm em doenças genéticas humanas
EP2526113B1 (en) * 2010-01-22 2016-08-10 Sirna Therapeutics, Inc. Post-synthetic chemical modification of rna at the 2'-position of the ribose ring via "click" chemistry
US20130037977A1 (en) 2010-04-08 2013-02-14 Paul A. Burke Preparation of Lipid Nanoparticles
KR102029657B1 (ko) * 2011-06-08 2019-10-08 닛토덴코 가부시키가이샤 표적 약물 전달체 및 ｓｉＲＮＡ 활성을 증가시키는 화합물

Also Published As

Publication number Publication date
CA2853689C (en) 2020-06-30
CA2853685C (en) 2019-09-03
ES2721325T3 (es) 2019-07-31
RU2014122432A (ru) 2015-12-10
CY1121495T1 (el) 2020-05-29
JP2017165748A (ja) 2017-09-21
RU2647476C2 (ru) 2018-03-15
PT2773326T (pt) 2019-04-23
CN103906504A (zh) 2014-07-02
TR201904389T4 (tr) 2019-04-22
DK2773326T3 (en) 2019-04-15
WO2013093648A3 (en) 2013-10-24
US20130164400A1 (en) 2013-06-27
WO2013064911A3 (en) 2013-10-24
TW201323020A (zh) 2013-06-16
AU2012356239B2 (en) 2016-09-22
RU2642640C2 (ru) 2018-01-25
TWI618548B (zh) 2018-03-21
EP2773328A2 (en) 2014-09-10
CN103906504B (zh) 2017-11-17
AU2012330819A1 (en) 2014-05-15
JP6149041B2 (ja) 2017-06-14
EP3673898A1 (en) 2020-07-01
JP6133883B2 (ja) 2017-05-24
WO2013064911A2 (en) 2013-05-10
AU2012356239A1 (en) 2014-05-29
CN103906503B (zh) 2016-12-14
EP3485875A1 (en) 2019-05-22
EP2773326B1 (en) 2019-02-20
JP2015502345A (ja) 2015-01-22
SI2773326T1 (sl) 2019-04-30
TW201325634A (zh) 2013-07-01
CN103906503A (zh) 2014-07-02
KR102056702B1 (ko) 2019-12-17
KR20140097276A (ko) 2014-08-06
TWI615156B (zh) 2018-02-21
JP6442551B2 (ja) 2018-12-19
KR20140101748A (ko) 2014-08-20
WO2013093648A2 (en) 2013-06-27
HRP20190481T1 (hr) 2019-05-03
PL2773326T3 (pl) 2019-06-28
EP2773326A2 (en) 2014-09-10
AU2012330819B2 (en) 2017-08-31
CA2853689A1 (en) 2013-06-27
LT2773326T (lt) 2019-04-25
CA2853685A1 (en) 2013-05-10
RS58562B1 (sr) 2019-05-31
TWI626952B (zh) 2018-06-21
JP2014534232A (ja) 2014-12-18
KR102046968B1 (ko) 2019-12-02
RU2014122433A (ru) 2015-12-10
US8956572B2 (en) 2015-02-17
TW201731491A (zh) 2017-09-16

Similar Documents

Publication Publication Date Title
HRP20190481T1 (hr) Postupak za sterilnu pripravu nanočestica lipid-nukleinska kiselina
IL263389B (en) A method for the production of modified 5-fluoro-1h-pyrazolopyridines
ZA201401133B (en) Method for producing ternesite
EP2937329A4 (en) PROCESS FOR PRODUCING ACETIC ACID
IL231549A0 (en) A method for preparing glufosinate
PL2675539T3 (pl) Sposób wytwarzania poli(kwasu hydroksykarboksylowego)
SG2014005623A (en) Method for producing alpha-hydroxycarboxylic acid esters
ZA201304938B (en) Process for producing nitrile-fatty acid compounds
EP2735615A4 (en) PROCESS FOR PRODUCING ORGANIC ACID
PL2714589T3 (pl) Dwuwodzianowo-półwodzianowy sposób wytwarzania kwasu fosforowego
EP2784063A4 (en) PROCESS FOR THE PREPARATION OF BETA-MERCAPTOCARBONIC ACID
EP2687515A4 (en) PROCESS FOR PREPARING A PYRAZOL CARBOXYLIC ACID DERIVATIVE
IL231877A0 (en) A method for the production of dithiene tetracarboximides
EP2857510A4 (en) PROCESS FOR PREPARING 3-ACETYLAMINO-4-HYDROXYBENZOIC ACID
EP2796562A4 (en) METHOD FOR PRODUCING AN OPTICALLY ACTIVE SUBSTITUTED AMINO ACID
SG11201401916PA (en) Method for producing formic acid
EP2757089A4 (en) PROCESS FOR PRODUCING AMINO ACID
IL231878A0 (en) A method for the production of dithiene tetracarboximides
EP2784064A4 (en) PROCESS FOR PRODUCTION OF BETA-MERCAPTOCARBOXYLIC ACID